Finance

Lists
BH3:FRA
PTC Therapeutics, Inc.
€56.84
-0.07%
(-0.040) 1D
Nov 13, 10:00:00 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for BH3...
Open
€56.16
High
€56.84
Low
€56.16
Mkt. cap
5.30B
Volume
0.00
52-wk high
€77.02
52-wk low
€51.64
No. of employees
991
Open
€56.16
High
€56.84
Low
€56.16
Mkt. cap
5.30B
Volume
0.00
52-wk high
€77.02
52-wk low
€51.64
No. of employees
991
News stories
From web sources and news partners
Profile
PTC Therapeutics, Inc. is an U.S.-based pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapies that alter gene expression via post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websiteptcbio.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
164.68M
272.55M
360.52M
357.81M
Cost of goods sold
140.08M
129.70M
119.07M
129.02M
Cost of revenue
140.08M
129.70M
119.07M
129.02M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
96.87M
86.18M
80.63M
80.08M
Operating expense
106.22M
97.76M
92.47M
92.68M
Total operating expenses
246.30M
227.46M
211.54M
221.69M
Operating income
-81.62M
45.09M
148.98M
136.11M
Other non operating income
-10.81M
-1.00M
35.00K
127.00K
EBT including unusual items
-139.08M
-2.46M
97.54M
-41.09M
EBT excluding unusual items
-150.16M
-3.55M
100.93M
88.07M
Income tax expense
-4.12M
347.00K
14.05M
10.60M
Effective tax rate
2.96%
-14.09%
14.40%
-25.81%
Other operating expenses
-
-
-
-
Net income
-134.96M
-2.81M
83.50M
-51.69M
Net profit margin
-81.96%
-1.03%
23.16%
-14.45%
Earnings per share
-1.80
-0.03
0.92
-0.39
Interest and investment income
5.30M
17.98M
18.12M
20.93M
Interest expense
-57.32M
-67.02M
-66.60M
-67.90M
Net interest expenses
-52.03M
-49.03M
-48.48M
-46.97M
Depreciation and amortization charges
-
-
-
-
EBITDA
-68.72M
60.50M
164.85M
152.93M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps